 Antirheumatic Agents
"Antirheumatic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that are used to treat RHEUMATOID ARTHRITIS.
| Descriptor ID |
D018501
|
| MeSH Number(s) |
D27.505.954.329
|
| Concept/Terms |
Antirheumatic Agents- Antirheumatic Agents
- Anti-Rheumatic Drugs
- Anti Rheumatic Drugs
- Antirheumatic Drugs
- Anti-Rheumatic Agents
- Anti Rheumatic Agents
Antirheumatic Drugs, Disease-Modifying- Antirheumatic Drugs, Disease-Modifying
- Antirheumatic Drugs, Disease Modifying
- DMARD
- Disease-Modifying, Antirheumatic Second-Line Drugs
- Disease Modifying, Antirheumatic Second Line Drugs
- Antirheumatic Disease-Modifying Second-Line Drugs
- Antirheumatic Disease Modifying Second Line Drugs
- Disease-Modifying Antirheumatic Drugs
- Disease Modifying Antirheumatic Drugs
|
Below are MeSH descriptors whose meaning is more general than "Antirheumatic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antirheumatic Agents".
This graph shows the total number of publications written about "Antirheumatic Agents" by people in this website by year, and whether "Antirheumatic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 | | 1997 | 2 | 1 | 3 | | 1999 | 3 | 0 | 3 | | 2000 | 1 | 0 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 1 | 0 | 1 | | 2004 | 3 | 0 | 3 | | 2005 | 4 | 0 | 4 | | 2006 | 0 | 2 | 2 | | 2007 | 2 | 0 | 2 | | 2009 | 3 | 2 | 5 | | 2010 | 3 | 6 | 9 | | 2011 | 4 | 2 | 6 | | 2012 | 4 | 3 | 7 | | 2013 | 3 | 4 | 7 | | 2014 | 7 | 3 | 10 | | 2015 | 8 | 2 | 10 | | 2016 | 5 | 1 | 6 | | 2017 | 1 | 1 | 2 | | 2018 | 3 | 1 | 4 | | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antirheumatic Agents" by people in Profiles.
-
Whittington MD, McQueen RB, Ollendorf DA, Chapman RH, Kumar VM, Synnott PG, Agboola F, Campbell JD. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. J Manag Care Spec Pharm. 2019 Jan; 25(1):80-87.
-
England BR, Sayles H, Michaud K, Thiele GM, Poole JA, Caplan L, Sauer BC, Cannon GW, Reimold A, Kerr GS, Baker JF, Mikuls TR. Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survival. Clin Rheumatol. 2018 Nov; 37(11):2907-2915.
-
Bloom JL, Darst JR, Prok L, Soep JB. A case of Henoch-Schonlein Purpura with dilated coronary arteries. Pediatr Rheumatol Online J. 2018 Sep 04; 16(1):54.
-
Wood PR, Caplan L. Drug-Induced Gastrointestinal and Hepatic Disease Associated with Biologics and Nonbiologic Disease-Modifying Antirheumatic Drugs. Rheum Dis Clin North Am. 2018 02; 44(1):29-43.
-
Popp RA, Rascati K, Davis M, Patel U. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis. Pharmacotherapy. 2018 02; 38(2):172-180.
-
Fechtner S, Fox DA, Ahmed S. Transforming growth factor ß activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology (Oxford). 2017 07 01; 56(7):1060-1068.
-
Fechtner S, Singh A, Chourasia M, Ahmed S. Molecular insights into the differences in anti-inflammatory activities of green tea catechins on IL-1ß signaling in rheumatoid arthritis synovial fibroblasts. Toxicol Appl Pharmacol. 2017 08 15; 329:112-120.
-
Cavalli G, Koenders M, Kalabokis V, Kim J, Tan AC, Garlanda C, Mantovani A, Dagna L, Joosten LA, Dinarello CA. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (Oxford). 2016 Dec; 55(12):2220-2229.
-
Baker JF, Sauer BC, Cannon GW, Teng CC, Michaud K, Ibrahim S, Jorgenson E, Davis L, Caplan L, Cannella A, Mikuls TR. Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis. Arthritis Rheumatol. 2016 08; 68(8):1818-27.
-
Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Joseph GJ, Harrison DJ, Sauer BC. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. Adv Ther. 2016 08; 33(8):1347-59.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|